Abstract:Dear Sir, We would like to thank Dr Subramanian and Dr Quek for their insightful and interesting article, “Osimertinib and jaw osteonecrosis? A case report,” in which they cited our study. We read their letter with interest, and we have a few additional comments on this issue and the insights gained from their case report. According to previous studies, medication-related osteonecrosis of the jaw (MRONJ) is predominantly found in patients who have used antiangiogenic drugs, including VEGFRTKIs such as sunitinib, sorafenib and bevacizumab, and bisphosphonates (BPs). However, there is no description of this adverse event associated with the use of EGFR-TKIs such as gefitinib and erlotinib. The case report presented in their letter highlights the likelihood of jaw osteonecrosis occurring as adverse effect of the use of Osimertinib. Indeed, jaw osteonecrosis was not identified as an adverse effect in our study. So far, we have not encountered this rare adverse effect related to Osimertinib administration in clinical practice, and we did not find corresponding reports after consulting the relevant literature. It is a meaningful issue worthy of our attention and exploration. The lack of a large sample of clinical data pertaining to infrequent adverse effects has always been one of the most challenging problems in clinical practice. The identification of factors that can predict the occurrence of adverse effects, especially rare ones, will contribute to optimizing the administration of drugs. However, there are still several doubts and points of confusion regarding this case. First, it is crucial to determine whether osteonecrosis of the jaw after dental extractions was solely related to the use of oral Osimertinib in this lung cancer patient. Second, the patient described in this letter had extensive and irreparable dental caries. The jaw osteonecrosis observed after the dental extractions were performed may have been a preexisting condition involved in making the surgical extractions necessary. Third, antiresorptives are well recognized as a cause of MRONJ, and the most commonly publicized antiresorptives are the BPs. It should be highlighted that no such drugs were used before the dental extractions in this patient. Moreover, in addition to the bone metastasis involving her left hip, whether the tumor in this patient had metastasized to her skull or jaw should be further identified. Jaw osteonecrosis may be associated with skull or jaw metastases. Due to the presence of individually relevant factors, it remains difficult to establish all the compounding factors that may have led to her jaw osteonecrosis; however, the key component appears to be the administration of Osimertinib. The numerous factors involved in these cases, such as intrinsic dental caries and extractions, as well as the recent addition of Osimertinib, emphasize the fact that jaw necrosis is a multifactorial condition with the implicated drugs exerting effects on both hard and soft tissues. Given that there are multiple factors that could be involved, we still need to exclude the possibility that other related factors were the cause of MRONJ. Therefore, more investigations are required to support these findings and to comprehensively describe the possible risk of MRONJ associated with Osimertinib. Nevertheless, we can obtain some important hints from this first case report. First, there is emerging evidence that Osimertinib is implicated as a causative agent for osteonecrosis of the jaw. This case of jaw necrosis should raise a red flag, and oncologists as well as dentists and oral and maxillofacial surgeons should be aware of the potential for the development of MRONJ as a result of surgical intervention with Osimertinib treatment. Second, whether certain factors can predict the occurrence of rare adverse effects needs to be further explored, such as the dental caries and potential bone metastases observed in this case. Additionally, if patients have dental caries and mandibular/skull metastases or if they plan to use osimertinib concomitantly with BPs, we should consider whether patients should receive appropriate oral health care for dental caries prior to starting osimertinib treatment. Collectively, this case suggests that we should take these aspects into consideration for patients receiving Osimertinib treatment. At the same time, to prevent the occurrence of adverse effects, we need to monitor patients to effectively manage their treatment. Yours sincerely, Lilan Yi Peng Luo Jian Zhang

The Importance of Dental Screening Prior to Commencing Anti-Resorptive Therapy for Treatment of Cancer: A Case Report and Discussion

Dental pathologies in tumor patients with bone metastases or multiple myeloma scheduled for antiresorptive therapy

How we manage medication-related osteonecrosis of the jaw

Medication-related osteonecrosis of the jaw: A disease of significant importance for older patients

THU442 A Case Of Early Medication Related Osteonecrosis Of The Jaw In Patient Receiving Intravenous Zoledronate For Treatment Of Osteoporosis

Peri‐implant medication‐related osteonecrosis of the jaw mimicking endodontic disease in a cancer patient: A case report

Risk factors for developing medication-related osteonecrosis of the jaw when preserving the tooth that can be a source of infection in cancer patients receiving high-dose antiresorptive agents: a retrospective study

A review of dental treatment of head and neck cancer patients, before, during and after radiotherapy: part 1

A systematic review of dental disease in patients undergoing cancer therapy

An audit of dental assessments including orthopantomography and timing of dental extractions before radiotherapy for head and neck cancer

Does inflammatory dental disease affect the development of medication-related osteonecrosis of the jaw in patients using high-dose bone-modifying agents?

Preventing, identifying, and managing medication-related osteonecrosis of the jaw: a practical guide for nurses and other allied healthcare professionals

Osimertinib: Another medication related to osteonecrosis of the jaws? A case report and literature review

Author's Reply To: Osimertinib and Jaw Osteonecrosis? A Case Report

Implication of dental insurance status on patterns of pre-radiation dental extraction and risk of osteoradionecrosis of the jaw in head-and-neck cancer patients

Prevention of osteoradionecrosis in patients with head and neck cancer treated with radiation therapy

Bridging the gap — Establishing a dental-oncology service in a cancer centre

Clinical practice guidelines for dental management prior to radiation for head and neck cancer

Potential role of comprehensive dental care in preventing medication related osteonecrosis of the jaw (MRONJ): a single centre study

The Trend of Dental Check-Up And Incidence of Dental Complications Following The Use of Bone Modifying Agents In Patients With Metastatic Breast And Prostate Cancer: Analysis of Data From The Korean National Health Insurance Service

Effect of Antiresorptive Drugs on Osseointegrated Dental Implants: A Systematic Review